Pascal Biosciences Inc stock analysis
Pascal Biosciences Inc (8DZ) Stock Price & Analysis
8DZ Stock Chart & Stats
- Day’s Range
- EUR 0.00 - EUR 0.02
- 52-Week Range
- EUR 0.00 - EUR 0.05
- Previous Close
- EUR 0.01
- Volume
- N/A
- Average Volume (3M)
- 1,167
- Market Cap
- EUR 504.21K
- Enterprise Value
- EUR 1.32M
- Total Cash (Recent Filing)
- EUR 60.85K
- Total Debt (Recent Filing)
- EUR 394.63K
- Price to Earnings (P/E)
- ―
- Beta
- -3.68
- Next Earnings
- Mar 25, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Manageable Leverage
Moderate leverage and positive equity provide a stronger financial foundation than the company had in earlier periods. This reduces balance-sheet strain, preserves flexibility for operations, and gives management more capacity to address losses without relying entirely on additional borrowing.
Positive Cash Generation
The shift to positive operating and free cash flow is an important improvement in internal funding capacity. If maintained, it can reduce dependence on external financing and support ongoing business activities, although durability remains tied to stabilizing revenue and improving profitability.
Improving Gross Margin
Higher gross margin and a materially smaller EBITDA loss indicate progress in the economics of the business, even though profitability remains negative. Continued improvement could strengthen operating leverage and move the company closer to sustainable earnings if revenue contraction is reversed.
Bears Say
Sharp Revenue Contraction
A sharply contracting top line weakens the company’s ability to absorb fixed operating costs and sustain investment in its business. Persistent revenue pressure would limit the benefit of margin improvements, reduce operating leverage, and make a durable path to profitability more difficult.
Persistent Losses
Ongoing net and operating losses show that the business is not yet converting its activities into sustainable profits. Negative returns on equity can gradually erode financial resources and restrict the company’s ability to reinvest, strengthen its balance sheet, or fund growth internally.
Weakening Cash-Flow Trend
Positive cash flow is tempered by its decline versus the prior period and modest coverage relative to revenue scale. This suggests limited cash-generation resilience, leaving less room to absorb continued operating losses or fund development unless revenue stabilizes and cash conversion improves.
8DZ FAQ
What was Pascal Biosciences Inc’s price range in the past 12 months?
What is Pascal Biosciences Inc’s market cap?
When is Pascal Biosciences Inc’s upcoming earnings report date?
How were Pascal Biosciences Inc’s earnings last quarter?
Is Pascal Biosciences Inc overvalued?
Does Pascal Biosciences Inc pay dividends?
What is Pascal Biosciences Inc’s EPS estimate?
How many shares outstanding does Pascal Biosciences Inc have?
What happened to Pascal Biosciences Inc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Pascal Biosciences Inc?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Pascal Biosciences Inc
Nevis Brands Inc. engages in the development and sale of cannabis products in the United States. It offers hemp derived THC beverages under the Major brand name. The company was formerly known as Pascal Biosciences Inc. and changed its name to Nevis Brands Inc. in June 2023. Nevis Brands Inc. is headquartered in Seattle, Washington.
- Sector
- Consumerdefensive
- Industry
- Beverages - Non-Alcoholic
- CEO
- John Kueber
- Employees
- 2
- Website
- www.nevisbrands.com
- Address
- 1900 Airport Way South, Seattle, WA, 98134, US
Pascal Biosciences Inc (8DZ) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 4 | 3 |
| Technical Analysis | 2 | 4 | 3 |
| Moving Averages | 10 | 0 | 0 |








